Many consumers trust that a Certificate of Analysis (COA) guarantees product safety, but without strict regulatory oversight, that’s not always the case. Mislabeling, unverified testing, and misleading claims are widespread in the CBD market—particularly in medical cannabis, consumable hemp, and many other nutraceutical products, which lack the stringent oversight seen in pharmaceutical manufacturing.This white paper uncovers misleading marketing tactics, highlights the risks of unregulated CBD, and provides insights into what consumers and businesses should look for in a truly safe, high-quality, and consistent product.
Download the white paper to learn more and help raise awareness about the need for higher standards in the CBD industry.